Biotech

All Articles

Actinogen's cortisol blocker fails phase 2 anxiety research study

.Actinogen Medical's cortisol blocker has skipped the major endpoint of a period 2 research in anxie...

Bivictrix determines going exclusive only method to take ADC in to center

.Antibody-drug conjugates (ADCs) have been at the center of many a billion-dollar biobuck licensing ...

TPG leadings up funds to $580M for investments all over life scientific researches

.Property manager TPG, which has actually assisted biotechs like Sionna Therapies and also Santa Ana...

Merck quits stage 3 TIGIT test in bronchi cancer cells for impossibility

.Merck &amp Co.'s TIGIT program has suffered one more misfortune. Months after shuttering a phase 3 ...

After a challenging year, Exscientia folds in to Recursion

.After a year described through pipe cuts, the departure of its own chief executive officer and disc...

Cullinan, after $25M offer, hands back bispecific to Port

.Cullinan Rehab was impressed sufficient along with Harbour BioMed's bispecific invulnerable activat...

A closer look at Fierce Biotech's Tough 15

.Within this week's episode of "The Leading Line," our company're diving in to Strong Biotech's annu...

Lilly deals with phase 2 breakdown of tau-targeting med

.The confetti is still soaring from Eli Lilly's celebration commemorating the commendation of Alzhei...

Biogen CMO Maha Radhakrishnan participates in Sofinnova-- Chutes &amp Ladders

.Welcome to recently's Chutes &amp Ladders, our summary of considerable management hirings, shooting...

Lykos are going to ask FDA to reconsider its selection observing denial of MDMA therapy for post-traumatic stress disorder

.Adhering to an unsatisfactory revealing for Lykos Therapeutics' MDMA applicant for trauma at a rece...